Holen Sie sich die Stockscreener-App
13.04
0.91%
-0.12
Vorhandelsmarkt:
12.90
-0.14
-1.07%
Schlusskurs vom Vortag:
$13.16
Offen:
$13.04
24-Stunden-Volumen:
1.27M
Relative Volume:
1.48
Marktkapitalisierung:
$1.19B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-249.31M
KGV:
-3.9396
EPS:
-3.31
Netto-Cashflow:
$-209.70M
1W Leistung:
-16.78%
1M Leistung:
-30.71%
6M Leistung:
-42.88%
1J Leistung:
-40.75%
1-Tages-Spanne:
$12.62
$13.23
1-Wochen-Bereich:
$12.62
$15.95
52-Wochen-Spanne:
$12.62
$32.52
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Firmenname
Rocket Pharmaceuticals Inc
Sektor
Branche
Telefon
646-440-9100
Adresse
350 FIFTH AVENUE, NEW YORK, NY
Vergleichen Sie RCKT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| RCKT | 13.04 | 1.19B | 0 | -249.31M | -209.70M | -3.31 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-01 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-11-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-11-01 | Eingeleitet | BTIG Research | Buy |
| 2022-07-08 | Eingeleitet | Raymond James | Outperform |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2021-02-18 | Eingeleitet | Needham | Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-12-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-07-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2019-11-06 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-26 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-04-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-03-15 | Eingeleitet | BofA/Merrill | Buy |
| 2019-02-05 | Eingeleitet | Oppenheimer | Outperform |
| 2018-09-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-07-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Rocket Pharmaceuticals Inc Aktie (RCKT) Neueste Nachrichten
Needham & Company LLC Reiterates Buy Rating for Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Cantor Fitzgerald Reaffirms “Overweight” Rating for Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Earns “Buy” Rating from Canaccord Genuity Group - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Earns Buy Rating from Chardan Capital - Defense World
Rocket Pharmaceuticals Advances Genetic Therapies Pipeline - TipRanks
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst - AOL
Leerink Partners Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price - MarketBeat
Cantor Fitzgerald Reiterates Overweight Rating for Rocket Pharmaceuticals (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals' (RCKT) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Rocket Pharmaceuticals shares hold strong with Buy rating By Investing.com - Investing.com UK
First Turn Management LLC Purchases 60,317 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharma reports promising Phase 1 results for Danon disease therapy - Investing.com Australia
Rocket Pharma Stock Slips Despite New Long-Term Data On Phase-I Study; Retail Sentiment Slides - Asianet Newsable
Rocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 52-Week LowHere's What Happened - MarketBeat
Rocket Pharma's Danon Disease Treatment Shows 5-Year Success in Phase 1 Trial | RCKT Stock News - StockTitan
Rocket Pharmaceuticals is Now Oversold (RCKT) - Nasdaq
When (RCKT) Moves Investors should Listen - Stock Traders Daily
Chardan Capital Has Strong Estimate for RCKT FY2024 Earnings - MarketBeat
RCKT stock touches 52-week low at $15.96 amid market challenges - Investing.com India
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Rocket Pharma to Present Groundbreaking Danon Disease Gene Therapy Data at AHA 2024 | RCKT Stock News - StockTitan
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline In Focus - Barchart
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus - Yahoo Finance
Privium Fund Management B.V. Has $5.45 Million Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Analysts Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Price Target at $51.75 - MarketBeat
Wellington Management Group LLP's Strategic Acquisition in Rocke - GuruFocus.com
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference - BioSpace
Rocket Pharmaceuticals' (RCKT) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Rocket Pharmaceuticals: Q3 Earnings Snapshot - Houston Chronicle
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress - Yahoo Finance
Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41% - Simply Wall St
Here's Why We're Watching Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Situation - Yahoo Finance
Harbor Capital Advisors Inc. Has $3.11 Million Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals executive sells $51,205 in common stock - Investing.com
Rocket Pharmaceuticals executive sells $51,205 in common stock By Investing.com - Investing.com UK
Long Term Trading Analysis for (RCKT) - Stock Traders Daily
(RCKT) Trading Report - Stock Traders Daily
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ - GlobeNewswire
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - India Shorts
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 5.3%Here's What Happened - MarketBeat
Fanconi Anemia Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies | Foresee Pharma, Rocket Pharma, John Diaz, Novartis, Sierra Oncology - The Globe and Mail
Scotiabank Initiates Coverage of Rocket Pharmaceuticals (RCKT) with Sector Outperform Recommendation - MSN
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap UpWhat's Next? - MarketBeat
Investors in cash trouble should check out Rocket Pharmaceuticals Inc (RCKT) - SETE News
Rocket Pharmaceuticals (NASDAQ:RCKT) Now Covered by Analysts at Scotiabank - MarketBeat
The Attractiveness of Investing In Rocket Pharmaceuticals Inc (RCKT) is Growing - Knox Daily
Rocket Pharmaceuticals Inc (RCKT)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Recent Insider Activity Could Benefit Pacific Biosciences of California Inc (PACB) - Knox Daily
Verisk Analytics Inc [VRSK] Investment Appeal on the Rise - Knox Daily
Rocket Pharmaceuticals Inc (RCKT)’s stock chart: A technical perspective - US Post News
Finanzdaten der Rocket Pharmaceuticals Inc-Aktie (RCKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.69%
6.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):